Key facts
| Recalling firm | Eli Lilly & Company |
|---|---|
| Manufacturer | Eli Lilly and Company |
| Brand name | HUMALOG |
| Product description | Sterile Diluent, HUMALOG U-100 (insulin lispro injection), HUMULIN R U-100 REGULAR (insulin human injection), Insulin Lispro Injection u-100, 10 mL, Use ONLY with Insulins listed on carton, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285. NDC: 0002-0800-01 |
| Classification | Class II |
| Recall number | D-0445-2024 |
| Report date | Not disclosed in the FDA record. |
| Status | Completed |
| Reason for recall | CGMP Deviations |
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Sterile Diluent, HUMALOG U-100 (insulin lispro injection), HUMULIN R U-100 REGULAR (insulin human injection), Insulin Lispro Injection u-100, 10 mL, Use ONLY with Insulins listed on carton, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285. NDC: 0002-0800-01 should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Eli Lilly & Company. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Eli Lilly & Company should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Eli Lilly & Company directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
What this classification means
A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
Eli Lilly & Company’s FDA history
Argus HQ has recorded 1 total FDA action tied to Eli Lilly & Company: 0 warning letters, 1 recall, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- Where can I verify this recall directly with FDA?
- The verbatim FDA record is the source of truth for every recall Argus HQ tracks — always confirm against fda.gov before acting.
- Is Sterile Diluent, HUMALOG U-100 (insulin lispro injection), H recalled?
- Yes. FDA lists a Class II recall by Eli Lilly & Company for Sterile Diluent, HUMALOG U-100 (insulin lispro injection), HUMULIN R U-100 REGULAR (insulin human injection), Insulin Lispro Injection u-100, 10 mL, Use ONLY with Insulins listed on carton, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285. NDC: 0002-0800-01, reported 20240424, with status "Completed." FDA recall number: D-0445-2024.
- What is the recall class for Eli Lilly & Company's recall?
- FDA classified this recall as Class II. A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
- Why was Sterile Diluent, HUMALOG U-100 (insulin lispro injection), H recalled?
- FDA's recall record states the reason as: CGMP Deviations
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Eli Lilly & CompanyCompiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2024). FDA Class II Recall: HUMALOG by Eli Lilly & Company. Digital Empire LLC. Retrieved from https://argushq.ai/recall/eli-lilly-and-d-0445-2024-2024-04-24
"FDA Class II Recall: HUMALOG by Eli Lilly & Company." Argus HQ Research, Digital Empire LLC, 2024, argushq.ai/recall/eli-lilly-and-d-0445-2024-2024-04-24.
Argus HQ Research. "FDA Class II Recall: HUMALOG by Eli Lilly & Company." Digital Empire LLC. Accessed July 17, 2026. https://argushq.ai/recall/eli-lilly-and-d-0445-2024-2024-04-24.
@misc{argushq_argushq_ai_recall_eli_lilly_and_d_0445_2024_2024_04_24_2024,
title = {FDA Class II Recall: HUMALOG by Eli Lilly & Company},
author = {{Argus HQ Research}},
year = {2024},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/recall/eli-lilly-and-d-0445-2024-2024-04-24},
note = {Accessed: July 17, 2026}
}Source: FDA.gov — Recalls ↗

